Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias

被引:6
|
作者
Bentivenga, Giuseppe Mario [1 ]
Baiardi, Simone [1 ]
Mastrangelo, Andrea [1 ]
Zenesini, Corrado [2 ]
Mammana, Angela [2 ]
Polischi, Barbara [2 ]
Capellari, Sabina [1 ,2 ]
Parchi, Piero [1 ,2 ]
机构
[1] Univ Bologna, Dept Biomed & Neuromotor Sci DIBINEM, Bologna, Italy
[2] IRCCS Ist Sci Neurolog Bologna, Programma Neurogenet, Bologna, Italy
关键词
Cognitive Disorders; Dementia; Prion disease; SNAP-25; Neurogranin; Tau; Neurofilament; Synapses; Creutzfeldt-Jakob; PRION DISEASE; BIOMARKERS; CSF;
D O I
10.1186/s13195-023-01300-y
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background The levels of synaptic markers synaptosomal-associated protein 25 (SNAP-25) and neurogranin (Ng) have been shown to increase early in the cerebrospinal fluid (CSF) of patients with Creutzfeldt-Jakob disease (CJD) and to have prognostic potential. However, no validation studies assessed these biomarkers' diagnostic and prognostic value in a large clinical setting cohort of rapidly progressive dementia. Methods In this retrospective study, using commercially available immunoassays, we measured the levels of SNAP-25, Ng, 14-3-3, total-tau (t-tau), neurofilament light chain (NfL), and phospho-tau181 (p-tau) in CSF samples from consecutive patients with CJD (n = 220) or non-prion rapidly progressive dementia (np-RPD) (n = 213). We evaluated and compared the diagnostic accuracy of each CSF biomarker and biomarker combination by receiver operating characteristics curve (ROC) analyses, studied SNAP-25 and Ng CSF concentrations distribution across CJD subtypes, and estimated their association with survival using multivariable Cox regression analyses. Results CSF SNAP-25 and Ng levels were higher in CJD than in np-RPD (SNAP-25: 582, 95% CI 240-1250 vs. 115, 95% CI 78-157 pg/ml, p < 0.0001; Ng: 841, 95% CI 411-1473 vs. 390, 95% CI 260-766 pg/ml, p < 0.001). SNAP-25 diagnostic accuracy (AUC 0.902, 95% CI 0.873-0.931) exceeded that of 14-3-3 (AUC 0.853, 95% CI 0.816-0.889), t-tau (AUC 0.878, 95% CI 0.845-0.901), and the t-tau/p-tau ratio (AUC 0.884, 95% CI 0.851-0.916). In contrast, Ng performed worse (AUC 0.697, 95% CI 0.626-0.767) than all other surrogate biomarkers, except for NfL (AUC 0.649, 95% CI 0.593-0.705). SNAP-25 maintained a relatively high diagnostic value even for atypical CJD subtypes (AUC 0.792, 95% CI 0.729-0.854). In Cox regression analyses, SNAP-25 levels were significantly associated with survival in CJD (hazard ratio [HR] 1.71 95% CI 1.40-2.09). Conversely, Ng was associated with survival only in the most rapidly progressive CJD subtypes (sCJD MM(V)1 and gCJD M1) (HR 1.81 95% CI 1.21-2.93). Conclusions In the clinical setting, CSF SNAP-25 is a viable alternative to t-tau, 14-3-3, and the t-tau/p-tau ratio in discriminating the CJD subtypes from other RPDs. Additionally, SNAP-25 and, to a lesser extent, Ng predict survival in CJD, showing prognostic power in the range of CSF t-tau/14-3-3 and NfL, respectively.
引用
收藏
页数:13
相关论文
共 45 条
  • [31] Diagnostic accuracy of cerebrospinal fluid protein markers for sporadic Creutzfeldt-Jakob disease in Canada: a 6-year prospective study
    Michael B Coulthart
    Gerard H Jansen
    Elina Olsen
    Deborah L Godal
    Tim Connolly
    Bernard CK Choi
    Zheng Wang
    Neil R Cashman
    BMC Neurology, 11
  • [32] Diagnostic accuracy of cerebrospinal fluid protein markers for sporadic Creutzfeldt-Jakob disease in Canada: a 6-year prospective study
    Coulthart, Michael B.
    Jansen, Gerard H.
    Olsen, Elina
    Godal, Deborah L.
    Connolly, Tim
    Choi, Bernard C. K.
    Wang, Zheng
    Cashman, Neil R.
    BMC NEUROLOGY, 2011, 11
  • [33] 14-3-3 protein levels and isoform patterns in the cerebrospinal fluid of Creutzfeldt-Jakob disease patients in the progressive and terminal stages
    Shiga, Yusei
    Wakabayashi, Hideki
    Miyazawa, Koichi
    Kido, Hiroshi
    Itoyama, Yasuto
    JOURNAL OF CLINICAL NEUROSCIENCE, 2006, 13 (06) : 661 - 665
  • [34] Comparison of cerebrospinal fluid tau, ptau(181), synuclein, and 14-3-3 for the detection of Creutzfeldt-Jakob disease in clinical practice
    Fayolle, Martin
    Lehmann, Sylvain
    Delaby, Constance
    JOURNAL OF NEURAL TRANSMISSION, 2022, 129 (02) : 133 - 139
  • [35] Creutzfeldt Jakob disease:: diagnostic value of protein 14-3-3 and neuronal specific enolase assay in cerebrospinal fluid.
    Brandel, JP
    Beaudry, P
    Delasnerie-Lauprêtre, N
    Laplanche, JL
    REVUE NEUROLOGIQUE, 1999, 155 (02) : 148 - 151
  • [36] Diagnostic value of surrogate cerebrospinal fluid biomarkers for the clinical diagnosis of Creutzfeldt- Jakob disease: A 10-year review from a CJD referral laboratory
    Poggiolini, Ilaria
    Capellari, Sabina
    Ladogana, Anna
    McGuire, Lynne I.
    Green, Alison J. E.
    Pocchiari, Maurizio
    Parchi, Piero
    PRION, 2014, 8 : 125 - 125
  • [37] MM2-cortical-type sporadic Creutzfeldt-Jakob disease with early stage cerebral cortical pathology presenting with a rapidly progressive clinical course
    Niimi, Yoshiki
    Iwasaki, Yasushi
    Umemura, Toshitaka
    Tanaka, Fumiaki
    Yoshida, Mari
    Hashizume, Yoshio
    Kitamoto, Tetsuyuki
    Hirayama, Mikio
    Sobue, Gen
    NEUROPATHOLOGY, 2008, 28 (06) : 645 - 651
  • [38] Creutzfeldt-Jacob disease or other rapidly progressive dementia? Diagnostic and prognostic value of EEG, brain MRI and CSF features
    Castelli, Alessandro
    Placidi, Fabio
    Bonomi, Chiara Giuseppina
    Liguori, Claudio
    Pagano, Andrea
    Mari, Luisa
    Manfredi, Natalia
    Mercuri, Nicola
    Izzi, Francesca
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 96 - 96
  • [39] The cerebrospinal fluid 14-3-3 assay's diagnostic utility among clinically suspected Creutzfeldt-Jakob disease patients: The NIH experience
    Kenney, KL
    Hsich, G
    Brechtel, C
    Gibbs, CJ
    NEUROLOGY, 2002, 58 (07) : A250 - A250
  • [40] Evaluation of cerebrospinal fluid levels of VAMP-2 and SNAP-25 in a dementia with Lewy bodies clinical cohort stratified by Alzheimer’s pathophysiological biomarkers
    Alba Cervantes González
    Julie Goossens
    Elena Vera Campuzano
    Isabel Sala
    M. Belén Sánchez-Saudinós
    Íñigo Rodríguez-Baz
    Laia Lidón
    Danna Perlaza
    Alexandre Bejanin
    Annakaisa Haapasalo
    Juan Fortea
    Daniel Alcolea
    Alberto Lleó
    Eugeen Vanmechelen
    Olivia Belbin
    Alzheimer's Research & Therapy, 17 (1)